Division of Molecular Pathology, Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Division of Molecular Pathology, Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Semin Oncol. 2021 Apr;48(2):152-155. doi: 10.1053/j.seminoncol.2020.12.001. Epub 2021 Jan 4.
The current SARS-CoV-2 infection or the COVID 19 pandemic has taken the world by storm, where the best health care systems in the world seem to be overwhelmed and still this virus is eluding us as we are compelled to explore the preventive and/or therapeutic interventions to control the disease outbreak as well as to prevent deaths. In parallel to clinical services, laboratories have been overwhelmed with task of keeping up with ever increasing demand for testing. Real time PCR detection of COVID19 is the gold standard method, however, has certain shortcomings in terms of availability of infrastructure, reagents, consumables, and technical expertise. All these have paved the way for the alternative testing algorithms and strategies. Countries like United States and Italy have struggled with these issues. India has been criticized for not testing enough and not adopting the right policy, but has been managing the disease within its resource limited health care system to a fair extent. The present review provides the Indian perspective of COVID 19 testing, the journey from not testing enough in the past to a vast expanse and depth of testing in present time.
当前的 SARS-CoV-2 感染或 COVID-19 大流行已经席卷全球,世界上最好的医疗保健系统似乎已经不堪重负,而我们仍然无法控制这种病毒,因为我们被迫探索预防和/或治疗干预措施来控制疾病爆发以及预防死亡。除了临床服务之外,实验室还面临着满足不断增加的检测需求的艰巨任务。实时 PCR 检测是 COVID-19 的金标准方法,但在基础设施、试剂、耗材和技术专业知识的可用性方面存在某些缺点。所有这些都为替代检测算法和策略铺平了道路。美国和意大利等国家在这些问题上苦苦挣扎。印度因检测不足和未采取正确政策而受到批评,但在资源有限的医疗保健系统内对该疾病进行了一定程度的管理。本综述提供了 COVID-19 检测的印度视角,从过去检测不足到现在广泛而深入的检测的历程。